CRBU Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.6M
+7.2%
1.5M
-37.5%
2.4M
-39.2%
3.9M
+79.3%
2.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.6M
+7.2%
1.5M
-37.5%
2.4M
-39.2%
3.9M
+79.3%
2.2M
Operating Expenses
29.2M
+9.0%
26.8M
-6.4%
28.7M
-11.5%
32.4M
+2.5%
31.6M
R&D
21.3M
+12.7%
18.9M
-8.1%
20.6M
-13.5%
23.8M
+6.3%
22.4M
SG&A
7.9M
+0.1%
7.9M
-2.1%
8.1M
-6.0%
8.6M
-6.7%
9.2M
Operating Income
-27642000
-9.1%
-25339000
+3.6%
-26280000
+7.6%
-28453000
+3.2%
-29400000
EBITDA
-27052000
-9.5%
-24714000
+3.6%
-25631000
+7.7%
-27771000
+3.5%
-28769000
Net Income
-26612000
-9.6%
-24282000
+3.2%
-25085000
+5.3%
-26488000
+3.8%
-27548000
EPS (Basic)
$-0.25
-4.2%
$-0.24
+7.7%
$-0.26
+7.1%
$-0.28
+6.7%
$-0.30
EPS (Diluted)
$-0.25
-4.2%
$-0.24
+7.7%
$-0.26
+7.1%
$-0.28
+6.7%
$-0.30
Shares (Diluted)
107.5M
+6.5%
101.0M
+5.3%
95.9M
+1.4%
94.6M
+1.4%
93.3M
Caribou Biosciences (CRBU) — Financials